Company
TILT Biotherapeutics
- Biotech
- Headquarters:
- Finland, Finland
Description
TILT Biotherapeutics develops oncolytic viral immunotherapies that modify the tumor microenvironment to stimulate T‑cell responses and enhance combinations with checkpoint inhibitors and T‑cell therapies for solid tumors.
Related
ThelperThelper develops first-in-class antiviral antibody drug conjugates (ADCs) targeting virally encoded biomarkers in aggressive solid tumors…
Iovance Biotherapeutics ($IOVA)Iovance Biotherapeutics develops and manufactures tumor-infiltrating lymphocyte (TIL) cell therapies for treating solid tumors, running…
ORCA TherapeuticsORCA Therapeutics develops oncolytic virus immunotherapies for prostate cancer, producing lead therapeutic ORCA-010 for treatment-naive…
OncoGenOncoGen conducts research and microproduction for cancer, allergies and regenerative medicine, developing gene‑cell therapies, anti‑cancer…
Arsenal BioArsenal Bio develops in vivo T cell therapies and reprogrammed CAR T approaches for chronic diseases, including cancer and autoimmunity,…
Legend Biotech ($LEGN)Legend Biotech develops CAR-T cell therapies targeting blood cancers and solid tumors, advancing cellular research to expand treatment…
ONCOMATRYX BIOPHARMA SLOncomatryx develops biotechnology programs focused on modulating the tumor microenvironment.
AsimovAsimov designs and delivers integrated cells, genetic constructs, and cloud software to enable commercial-grade cell line and viral vector…
Intelligent TherapeuticsIntelligent Therapeutics engineers novel antibodies and antibody-like molecules for treating solid tumors and rare autoimmune diseases,…
ONK TherapeuticsONK Therapeutics develops off-the-shelf, optimally engineered natural killer (NK) cell therapies combining CAR and TRAIL variant constructs…
Vivere OncotherapiesVivere Oncotherapies develops bioengineered cancer immunotherapies designed to help patients’ immune systems target cold tumors and support…
Cleara BiotechCleara Biotech develops peptide-based therapeutics and biomarkers to selectively eliminate p53-impaired cancer cells, producing D-amino…